biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Post by chance18on Jan 04, 2019 3:47pm

93 Views

Post# 29188018

Isn’t Mon the 7th

Mark Day, Ph.D., director, president and chief executive officer will deliver the Bioasis company presentation at the 2nd Annual Neuroscience Innovation Forum on Mon., Jan. 6, 2019 at 12:05 p.m. PT in the Heritage Room at the Marines’ Memorial Club & Hotel, San Francisco.
Dr. Mark Day will also co-chair the Advances in Rare & Orphan Diseases panel on Mon., Jan. 6 at 2:10 p.m. PT.